Andrea F. Wainer - Jan 29, 2024 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Signature
/s/ Andrea F. Wainer by Jessica H. Paik, Attorney-in-Fact
Stock symbol
ABT
Transactions as of
Jan 29, 2024
Transactions value $
-$2,622,300
Form type
4
Date filed
1/31/2024, 05:30 PM
Previous filing
Dec 18, 2023
Next filing
Feb 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Options Exercise $1.11M +25K +38.45% $44.40 90K Jan 29, 2024 Direct
transaction ABT Common shares without par value Sale -$2.81M -25K -27.77% $112.50 65K Jan 29, 2024 Direct
transaction ABT Common shares without par value Options Exercise $1.05M +17.5K +26.91% $59.94 82.5K Jan 29, 2024 Direct
transaction ABT Common shares without par value Sale -$1.97M -17.5K -21.21% $112.50 65K Jan 29, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Options Exercise $0 -25K -65.32% $0.00 13.3K Jan 29, 2024 Common Shares 25K $44.40 Direct F1
transaction ABT Option (right to buy) Options Exercise $0 -17.5K -27.15% $0.00 46.9K Jan 29, 2024 Common Shares 17.5K $59.94 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
F2 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.